Redeye comments on Alligator Bioscience’s second quarter report.
Redeye raises its forecasts and Base Case for Addnode following a solid Q2 beating our estimates, mo...
Gross margin headwinds shadow ATH sales in Q2 Components and regulator capacity delay new portfolio ...
43% sales growth y-o-y, 37% organic We raise ’23e sales & EBIT estimates by 6% and 10% New fair valu...
Q2 net sales 6% below ABGSCe We trim our long-term EBIT estimates by 10% Fair value range of SEK 17-...
Organic growth down to 4-6% (cons. 6.2%) EBITDA down to 18-20% (cons.
Q2 due Thursday 21 July, 08:30 CET We expect strong orders and sales but weak EBIT 35x-13x ‘22e-‘23e...
Redeye is happy to see that Bong has been able to raise prices and restore gross margins faster than...
Bra fart i den underliggande försäljningen Bolaget visade en nettoomsättning under Q1'22 på 3,4 mkr ...
Fortsätter växa i utmanande onlinemiljö Omsättningen i Q2 uppgick till 129 mkr (106 mkr) motsvarande...
Redeye updates its valuation of Cantargia after the terms of its rights issue have been announced.
Raute reports Q2 results on Jul 22. We make downward revisions to our estimates due to the latest up...
Strong top line, 3% above ABGSC Underlying profitability weak, set to improve from now CEO announc...
Redeye lowers the estimates slightly in the light of a continued challenging market.
Redeye thinks the Q2 report was weak and indicated a hesitant market climate.
Serneke delivered a solid set of numbers with Q2 sales of SEK 2.
Effective operational delivery Improved debt metrics post value gains & acquisition 12.
NOI trimmed by ~1-2% and CEPS by ~4% We note rental income estimate potential Trading ~25% below 4-...
Q2 beat on sales, below on EBITA We expect the project market to slow, starting in H1’23 We lower ’2...
Continuing to outperform significantly Strong order intake, up by 43% 2022e EBIT up 28%, 2023-2024e ...
